Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
Int J Environ Res Public Health. 2019 12 27; 17(1)IJ

Abstract

Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI). However, the association between major adverse drug reactions (ADRs) and drug metabolic enzyme single-nucleotide polymorphisms (SNPs) remains unclear. In this study, 377 participants who received the 3HP regimen were recruited and examined for genotyping of CYP5A6, CYP2B6, CYP2C19, CYP2E1, and NAT2 SNPs. In our study, 184 participants (48.4%) developed ADRs. Moreover, CYP2C19 rs4986893 (TT vs. CC+CT, odds ratio [OR] [95% CI]: 2.231 [1.015-4.906]), CYP2E1 rs2070676 (CC vs. CG+GG, OR [95% CI]: 1.563 [1.022-2.389]), and CYP2E1 rs2515641 (CC vs. CT+TT, OR [95% CI]: 1.903 [1.250-2.898]) were associated with ADR development. In conclusion, CYP2C19 and CYP2E1 SNPs may provide useful information regarding ADRs in LTBI patients receiving the 3HP regimen.

Links

Publisher Full Text

ncbi.nlm.nih.gov

mdpi.com

PMC Free PDF

Authors+Show Affiliations

Yu YY

Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan. Department of Clinical Laboratory, Changhua Hospital, Changhua 513, Taiwan.

Tsao SM

Division of Chest, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan. Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung 402, Taiwan.

Yang WT

Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung 403, Taiwan.

Huang WC

Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan. Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 356, Taiwan. Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan. Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung 407, Taiwan.

Lin CH

Division of Chest, Changhua Christian Hospital, Changhua 500, Taiwan.

Chen WW

Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 500, Taiwan.

Yang SF

Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan. Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan.

Chiou HL

School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan. Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan.

Huang YW

Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan. Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 500, Taiwan.

MeSH

AdultAntitubercular AgentsArylamine N-AcetyltransferaseCytochrome P-450 Enzyme SystemDrug Administration ScheduleDrug Therapy, CombinationDrug-Related Side Effects and Adverse ReactionsFemaleHumansIsoniazidLatent TuberculosisMaleOdds RatioPolymorphism, Single NucleotideRifampin

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31892222

Citation

Yu, Ya-Yen, et al. "Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis." International Journal of Environmental Research and Public Health, vol. 17, no. 1, 2019.

Yu YY, Tsao SM, Yang WT, et al. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. Int J Environ Res Public Health. 2019;17(1).

Yu, Y. Y., Tsao, S. M., Yang, W. T., Huang, W. C., Lin, C. H., Chen, W. W., Yang, S. F., Chiou, H. L., & Huang, Y. W. (2019). Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. International Journal of Environmental Research and Public Health, 17(1). https://doi.org/10.3390/ijerph17010210

Yu YY, et al. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. Int J Environ Res Public Health. 2019 12 27;17(1) PubMed PMID: 31892222.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis. AU - Yu,Ya-Yen, AU - Tsao,Shih-Ming, AU - Yang,Wen-Ta, AU - Huang,Wei-Chang, AU - Lin,Ching-Hsiung, AU - Chen,Wei-Wen, AU - Yang,Shun-Fa, AU - Chiou,Hui-Ling, AU - Huang,Yi-Wen, Y1 - 2019/12/27/ PY - 2019/11/11/received PY - 2019/12/24/revised PY - 2019/12/25/accepted PY - 2020/1/2/entrez PY - 2020/1/2/pubmed PY - 2020/6/9/medline KW - adverse drug reaction KW - drug metabolic enzymes KW - latent tuberculosis KW - polymorphism JF - International journal of environmental research and public health JO - Int J Environ Res Public Health VL - 17 IS - 1 N2 - Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI). However, the association between major adverse drug reactions (ADRs) and drug metabolic enzyme single-nucleotide polymorphisms (SNPs) remains unclear. In this study, 377 participants who received the 3HP regimen were recruited and examined for genotyping of CYP5A6, CYP2B6, CYP2C19, CYP2E1, and NAT2 SNPs. In our study, 184 participants (48.4%) developed ADRs. Moreover, CYP2C19 rs4986893 (TT vs. CC+CT, odds ratio [OR] [95% CI]: 2.231 [1.015-4.906]), CYP2E1 rs2070676 (CC vs. CG+GG, OR [95% CI]: 1.563 [1.022-2.389]), and CYP2E1 rs2515641 (CC vs. CT+TT, OR [95% CI]: 1.903 [1.250-2.898]) were associated with ADR development. In conclusion, CYP2C19 and CYP2E1 SNPs may provide useful information regarding ADRs in LTBI patients receiving the 3HP regimen. SN - 1660-4601 UR - https://www.unboundmedicine.com/medline/citation/31892222/Association_of_Drug_Metabolic_Enzyme_Genetic_Polymorphisms_and_Adverse_Drug_Reactions_in_Patients_Receiving_Rifapentine_and_Isoniazid_Therapy_for_Latent_Tuberculosis_ L2 - https://www.mdpi.com/resolver?pii=ijerph17010210 DB - PRIME DP - Unbound Medicine ER -

Tags

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.Int J Environ Res Public Health. 2019 12 27; 17(1)IJ